Galapagos Announces Positive Topline Results in Phase 2 Study Using FRI Imaging Parameters While Investigating New Medication for IPF Patients.
The PINTA trial was a randomized, double-blind, placebo-controlled trial investigating a new drug for IPF patients: GLPG1205. The study recruited and included a total of 68 IPF patients. Participants were administered GLPG1205 or placebo.
The primary objective of the trial was to assess the change from baseline in FVC (in mL) over 26 weeks compared to placebo.
At week 26, patients receiving GLPG1205 on top of standard of care showed a smaller FVC decline, with a difference of 42mL versus placebo. In addition, the change in pulmonary lobar volume, as measured by FRI, correlates with the FVC decline observed.
The full press release can be read HERE.
Based on the results of this trial, Galapagos plans to progress GLPG1205 in a dose finding Phase 2b trial.
The full results of the PINTA trial will be submitted to a future medical conference and peer reviewed medical journals.
Categorised in: Miscellaneous / December 4, 2020 11:13 am /Tags: FRI, IPF, Pinta, Trial